Despite the integration of BCN Pharma, Faes’ Q2 top-line came under pressure primarily due to the decline in sales of Bilastine (due to the reduction in pollen allergies). However, the momentum was partly made-up by strong growth for Hidroferol. Interestingly, management’s efficient cost management ensured a significant rise in profits. With the gradual reopening of the economies, the recovery has been noticed in all the franchisees.
07 Aug 2020
Margins proliferated in Q2
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Margins proliferated in Q2
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
07 Aug 2020 -
Author:
Rishabh Kochar -
Pages:
3
Despite the integration of BCN Pharma, Faes’ Q2 top-line came under pressure primarily due to the decline in sales of Bilastine (due to the reduction in pollen allergies). However, the momentum was partly made-up by strong growth for Hidroferol. Interestingly, management’s efficient cost management ensured a significant rise in profits. With the gradual reopening of the economies, the recovery has been noticed in all the franchisees.